Xerostomia Therapeutics Market to Grow with a CAGR of 3.78% through 2028
Increase in the incidence of chronic diseases and increase in the aging
population is expected to drive the Global Xerostomia Therapeutics Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Xerostomia
Therapeutics Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Xerostomia Therapeutics
Market stood at USD 1.98 billion in 2022 and is anticipated to grow with a CAGR
of 3.78% in the forecast period, 2024-2028. The awareness among individuals
regarding Xerostomia Therapeutics has led to favorable market conditions for
the global Xerostomia Therapeutics market. Several factors contribute to the
growth of various Xerostomia Therapeutics products.
The global population is aging, with a substantial
increase in the elderly demographic. Xerostomia is more prevalent among older
individuals due to the natural aging process, as well as the use of medications
commonly associated with reduced saliva production. As the elderly population
grows, so does the demand for xerostomia therapeutics. Pharmaceutical companies
and healthcare providers are focusing on developing and offering effective
treatments for this age group, which is driving market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Xerostomia Therapeutics Market”
Many medications, including antihypertensives,
antidepressants, antihistamines, and anticholinergics, have dry mouth as a
common side effect. As the prevalence of chronic diseases rises, so does the
consumption of these medications. This, in turn, leads to a higher incidence of
xerostomia. The need for effective therapeutics to manage this condition is
growing, as patients seek relief from the discomfort and potential oral health
issues associated with dry mouth.
In October 2023, CL is committed to sustainability and
is taking steps to reduce its environmental impact. The company has set a goal
of becoming carbon neutral by 2040. In addition, CL is working to reduce its
use of plastic and to source more sustainable materials for its products.
Chronic illnesses, such as diabetes and Sjögren's
syndrome, are often associated with xerostomia. With the increasing prevalence
of these diseases worldwide, the number of individuals suffering from dry mouth
is also on the rise. Consequently, there is a growing demand for xerostomia
therapeutics, both pharmaceutical and non-pharmaceutical, to alleviate the
symptoms and improve the quality of life for these patients.
In today's fast-paced world, Dry mouth can be
distracting and uncomfortable, making it difficult to concentrate on tasks.
Xerostomia therapeutics help individuals regain their focus by alleviating dry
mouth symptoms, allowing them to work, study, or perform tasks more
effectively. Effective communication is vital in a fast-paced world, whether in
the workplace, social settings, or during important meetings. Xerostomia
therapeutics, such as lozenges or saliva substitutes, can reduce the discomfort
associated with speaking, making it easier for individuals to express
themselves clearly and confidently. Sustained Energy Levels: In a busy
environment, maintaining energy levels is crucial. Dry mouth can hinder the
consumption of water and food, potentially leading to dehydration and decreased
energy. Xerostomia therapeutics can improve hydration and promote better eating
habits, thus contributing to sustained energy throughout the day. Enhanced
Nutrition: Malnutrition and dietary deficiencies can result from persistent dry
mouth, as individuals may struggle to eat certain foods. Xerostomia
therapeutics help improve nutrition by facilitating the consumption of a wider
variety of foods, supporting overall health and vitality. Less Time Lost to
Discomfort: Dry mouth can lead to frequent breaks to drink water or address
discomfort. Xerostomia therapeutics reduce the need for these interruptions,
allowing individuals to stay on task and maintain productivity levels. Enhanced
Workplace Performance: In professional settings, improved oral comfort means
employees can focus on their work without the distraction of dry mouth
symptoms. This contributes to enhanced workplace performance and efficiency.
Advancements in medical research and technology have
led to the development of innovative treatment options for xerostomia. These
include prescription medications, saliva substitutes, and medical devices like
salivary stimulants. These new products and therapies offer more effective and
targeted solutions for managing dry mouth, which can significantly improve
patient outcomes.
In recent times, The use of various medications has
risen over time, contributing to a growing incidence of medication-induced dry
mouth. Xerostomia therapeutics help individuals manage this common side effect,
ensuring that they can continue necessary treatments without experiencing
excessive discomfort. Recent demographic shifts indicate a substantial increase
in the aging population worldwide. Age-related factors often lead to
xerostomia. Xerostomia therapeutics are invaluable for elderly individuals, as
they help maintain oral health and comfort, improving the quality of life for
this demographic. The prevalence of chronic diseases such as diabetes,
Sjogren's syndrome, and cancer, all of which are associated with xerostomia, is
on the rise. Xerostomia therapeutics play a critical role in managing dry mouth
symptoms in patients with these conditions. However, Limited Awareness and
Diagnosis may hinder market growth. Moreover, challenges related to Fragmented
Market and Treatment Approaches and Regulatory and Reimbursement Challenges may
pose obstacles to the Xerostomia Therapeutics market in the near future.
The Global Xerostomia Therapeutics Market is segmented
into type, product, regional distribution, and company
Based on its type, the OTC xerostomia therapeutics,
which include saliva substitutes, oral moisturizers, and lozenges, can be
purchased without a prescription. This ease of access means that individuals
experiencing dry mouth symptoms can obtain relief products conveniently from
local pharmacies, drugstores, or even online retailers without the need for a
healthcare provider's authorization. OTC products are readily available on
store shelves and online marketplaces. Consumers can purchase them on the spot or
have them delivered to their homes, offering immediate relief to those
suffering from the discomfort of xerostomia. In contrast, prescription-based
therapeutics may involve a delay in obtaining the treatment. OTC products
empower consumers to choose the specific xerostomia therapeutics that best suit
their needs. This freedom of choice allows individuals to select products based
on factors like taste, texture, ingredients, and personal preferences,
enhancing their overall experience and satisfaction. Many individuals prefer to
take control of their healthcare, especially for non-severe conditions like
xerostomia. OTC products enable self-care, giving individuals the autonomy to
manage their symptoms without the need for repeated visits to healthcare providers.
This self-care trend aligns with the broader movement toward preventive health
and wellness.
Based on region, North America segment is expected to
grow during the forecast period. North America boasts advanced
healthcare infrastructure with well-established healthcare systems, making it
easier for patients to access specialized treatments and for pharmaceutical
companies to introduce new xerostomia therapeutics. North America has a high
prevalence of chronic diseases like diabetes and autoimmune disorders, which
are often associated with xerostomia. This increases the demand for xerostomia
therapeutics in the region. The use of medications that can cause dry mouth is
also widespread in North America. This contributes to the high incidence of
xerostomia and drives the demand for treatments. The region is home to many
major pharmaceutical companies known for their commitment to research and
development. These companies focus on innovating xerostomia therapeutics,
introducing new and improved treatment options. Health insurance coverage in
North America is relatively common, making xerostomia therapeutics more
accessible to a larger portion of the population. Patients are more likely to
seek and afford treatment, contributing to the market's dominance.
The Asia-Pacific market is poised to be the
fastest-growing market, offering lucrative growth opportunities for Xerostomia
Therapeutics players during the forecast period. Factors such as Asia-Pacific
region are experiencing a growing middle class with increased disposable
income. This demographic shift leads to higher healthcare expenditure and
greater willingness to seek treatment for health conditions, including
xerostomia. The Asia-Pacific region has a significantly larger population
compared to North America. With an aging population and an increased incidence
of chronic diseases, there is a substantial pool of potential xerostomia
patients, which fuels market growth. The region is witnessing increased
healthcare awareness, and patients are becoming more informed about their
health conditions and available treatment options. Infrastructure improvements
and greater access to healthcare services, including dental care, are
contributing to the diagnosis and management of xerostomia in the region.
Major companies operating in Global Xerostomia
Therapeutics Market are:
- GlaxoSmithKline plc
- Church & Dwight Co., Inc.
- Colgate-Palmolive Company
- Hikma Pharmaceuticals PLC
- Pendopharm
- Sun Pharmaceuticals Industries Ltd
- Lupin Pharmaceuticals, Inc.
- Pfizer, Inc.
- Parnell Pharmaceuticals, Inc.
- Acacia Pharma
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“The Technological Advancements and Product Innovation
and increasing Awareness and Diagnosis are key drivers of the Xerostomia
Therapeutics market. In recent years, the growing emphasis on patient
well-being and the demand for personalized healthcare solutions drive the
adoption of xerostomia therapeutics that improve patients' quality of life.
Moreover, the growing consumer emphasis on preventative healthcare products has
enhanced production and marketing efforts. To meet the demands of the market,
manufacturers are increasingly incorporating cutting-edge technologies with
high production efficiency. Rising consumer acceptance and continuous product
innovation will further ensure the growth of the Xerostomia Therapeutics market
in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Xerostomia Therapeutics Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (OTC, Prescription),
By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Xerostomia Therapeutics Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Xerostomia Therapeutics Market.
Contact Us-
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
M:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com